Cipher Pharmaceuticals 향후 성장
Future 기준 점검 1/6
Cipher Pharmaceuticals (는) 각각 연간 2.1% 및 8.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 0.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14% 로 예상됩니다.
핵심 정보
2.1%
이익 성장률
0.76%
EPS 성장률
| Pharmaceuticals 이익 성장 | 40.7% |
| 매출 성장률 | 8.2% |
| 향후 자기자본이익률 | 13.98% |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 12 May 2026 |
최근 향후 성장 업데이트
Recent updates
분석 기사 • May 14
Investors Shouldn't Be Too Comfortable With Cipher Pharmaceuticals' (TSE:CPH) Earnings
Cipher Pharmaceuticals Inc. ( TSE:CPH ) announced strong profits, but the stock was stagnant. Our analysis suggests...
내러티브 업데이트 • May 08
CPH: Higher Cash Returns And Buybacks Will Support Future Upside
Analysts have lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E. These changes support a slightly higher fair value estimate.내러티브 업데이트 • Apr 23
CPH: Higher Cash Flow Plans And Buybacks Will Support Future Upside
Analysts have nudged their fair value estimate for Cipher Pharmaceuticals to CA$21 from CA$20, tying the CA$1 price target change to updated assumptions around revenue growth, profit margins and a slightly higher discount rate alongside a lower future P/E. Analyst Commentary Recent research points to a modestly higher fair value for Cipher Pharmaceuticals, with bullish analysts lifting their price target to CA$21 from CA$20.
내러티브 업데이트 • Apr 09
CPH: Fair Outlook Will Weigh Natroba Expansion And Acquisition Execution
Analysts have nudged their price target on Cipher Pharmaceuticals up to CA$21 from CA$20, citing updated assumptions that keep fair value broadly steady while fine tuning expectations around growth, margins, and P/E levels. Analyst Commentary The latest price target move to CA$21 from CA$20 signals only a modest reset in expectations, rather than a major shift in conviction.내러티브 업데이트 • Mar 26
CPH: Balanced Outlook Will Weigh New Drug Review And Acquisition Execution
Analysts recently lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, reflecting updated assumptions that combine a higher revenue growth outlook with slightly lower profit margin and future P/E expectations. Analyst Commentary The latest price target move to CA$21 suggests that covering analysts are refining their assumptions rather than making a sweeping change in their outlook.내러티브 업데이트 • Mar 12
CPH: New Drug Review Will Support Future Upside Potential
Analysts are maintaining their CA$18.60 price target on Cipher Pharmaceuticals. This reflects only small adjustments to their revenue growth and future P/E assumptions, rather than a change in their overall view of the stock.내러티브 업데이트 • Feb 26
CPH: New Drug Review And Strong Margins Will Support Further Upside
Analysts kept their CA$18.60 price target on Cipher Pharmaceuticals unchanged, citing only small tweaks to their revenue growth, profit margin and future P/E assumptions that did not materially shift their view of the stock’s value. What's in the News Health Canada accepted Cipher Pharmaceuticals' new drug submission for Natroba (Spinosad) for the treatment of head lice and scabies, moving the product into the formal review process (Key Developments).내러티브 업데이트 • Feb 11
CPH: Higher Margins And New Submission Will Support Future Upside
Analysts have trimmed their price target on Cipher Pharmaceuticals to reflect a more muted revenue growth outlook of 4.30% and a slightly higher discount rate of 6.25%, while still acknowledging a stronger projected profit margin of 39.46% and a broadly similar future P/E of 17.63. What's in the News Health Canada accepted Cipher Pharmaceuticals' new drug submission for Natroba (Spinosad), targeting head lice and scabies in the Canadian market (Key Developments).내러티브 업데이트 • Jan 26
CPH: Share Repurchases Will Drive Future Earnings Power And Upside Potential
Analysts have modestly adjusted their price target for Cipher Pharmaceuticals to reflect slightly updated assumptions around revenue growth of 10.48%, profit margin of 32.39%, and a future P/E of 17.81x. The overall fair value estimate remains at $18.60.내러티브 업데이트 • Jan 11
CPH: Share Repurchases Will Support Stronger Future Earnings Profile
Analysts have trimmed their price target on Cipher Pharmaceuticals by aligning slightly lower revenue growth and profit margin assumptions with a modestly higher future P/E. This keeps fair value around $18.60 and reflects a more measured outlook on the company’s earnings profile.내러티브 업데이트 • Dec 27
CPH: Share Repurchases And Rising Margins Will Support Stronger Future Earnings
Cipher Pharmaceuticals' analyst price target has been raised from 14.50 dollars to 18.60 dollars, as analysts cite slightly stronger expected revenue growth, modestly higher profit margins, and a richer future earnings multiple as justification for the upward revision. What's in the News Cipher Pharmaceuticals completed the latest tranche of its share repurchase program between July 1, 2025 and September 30, 2025, buying back 141,700 shares, or 0.56 percent of its float, for CAD 2.18 million (Key Developments) Under the buyback announced on May 1, 2025, the company has now repurchased a total of 371,978 shares, representing 1.46 percent of shares outstanding, for aggregate consideration of CAD 5.12 million (Key Developments) Valuation Changes The consensus analyst price target has risen significantly from 14.50 dollars to 18.60 dollars, reflecting a materially higher fair value assessment.내러티브 업데이트 • Dec 12
CPH: Share Buybacks Will Support Earnings And Maintain A Balanced Outlook
Analysts have nudged their price target on Cipher Pharmaceuticals higher, from 14.00 dollars to 14.50 dollars, citing stronger expected revenue growth, improved profit margins, and a more attractive forward earnings multiple despite a slightly higher discount rate. What's in the News Cipher Pharmaceuticals repurchased 141,700 shares between July 1 and September 30, 2025, totaling CAD 2.18 million and representing 0.56% of outstanding shares (company buyback update).분석 기사 • Nov 09
Cipher Pharmaceuticals Inc. (TSE:CPH) Analysts Are Pretty Bullish On The Stock After Recent Results
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders are probably feeling a little disappointed, since its shares fell...분석 기사 • Oct 10
These 4 Measures Indicate That Cipher Pharmaceuticals (TSE:CPH) Is Using Debt Extensively
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
내러티브 업데이트 • Sep 05
Expansion Into Canada Will Shape Global Dermatology Success
Cipher Pharmaceuticals' future P/E has risen sharply, indicating increased valuation relative to earnings, while the net profit margin is stable, resulting in no change to the consensus analyst price target at CA$17.90. What's in the News Cipher Pharmaceuticals is actively seeking accretive acquisitions and in-licensing opportunities, with a strategic focus on complementary U.S.-based assets and companies.분석 기사 • Aug 29
Cipher Pharmaceuticals Inc.'s (TSE:CPH) Shares Climb 27% But Its Business Is Yet to Catch Up
The Cipher Pharmaceuticals Inc. ( TSE:CPH ) share price has done very well over the last month, posting an excellent...분석 기사 • May 16
We Think That There Are More Issues For Cipher Pharmaceuticals (TSE:CPH) Than Just Sluggish Earnings
Investors weren't pleased with the recent soft earnings report from Cipher Pharmaceuticals Inc. ( TSE:CPH ). Our...분석 기사 • May 09
Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shares have had a really impressive month, gaining 29% after a shaky period...분석 기사 • Apr 28
Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
새로운 내러티브 • Feb 23
Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence
Strategic acquisitions and transitioning to an in-house sales team are aimed at reducing costs and boosting revenue and earnings for Cipher Pharmaceuticals.분석 기사 • Dec 13
We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Nov 14
Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think
Cipher Pharmaceuticals Inc.'s ( TSE:CPH ) earnings announcement last week contained some soft numbers, disappointing...분석 기사 • Nov 12
With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders won't be pleased to see that the share price has had a very rough...분석 기사 • Nov 09
Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders are probably feeling a little disappointed, since its shares fell...분석 기사 • Mar 23
There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shares have continued their recent momentum with a 26% gain in the last month...분석 기사 • Mar 22
Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)
The market rallied behind Cipher Pharmaceuticals Inc.'s ( TSE:CPH ) stock, leading do a rise in the share price after...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 65 | 27 | N/A | 40 | 2 |
| 12/31/2027 | 62 | 26 | N/A | 39 | 3 |
| 12/31/2026 | 53 | 22 | 30 | 28 | 4 |
| 3/31/2026 | 51 | 31 | 29 | 30 | N/A |
| 12/31/2025 | 50 | 27 | 30 | 30 | N/A |
| 9/30/2025 | 50 | 17 | 30 | 30 | N/A |
| 6/30/2025 | 48 | 12 | -59 | 21 | N/A |
| 3/31/2025 | 40 | 9 | -59 | 21 | N/A |
| 12/31/2024 | 33 | 12 | -60 | 20 | N/A |
| 9/30/2024 | 26 | 16 | -67 | 13 | N/A |
| 6/30/2024 | 22 | 23 | 17 | 17 | N/A |
| 3/31/2024 | 22 | 23 | 14 | 14 | N/A |
| 12/31/2023 | 21 | 20 | 16 | 16 | N/A |
| 9/30/2023 | 21 | 32 | 15 | 15 | N/A |
| 6/30/2023 | 20 | 28 | 13 | 13 | N/A |
| 3/31/2023 | 20 | 27 | 13 | 13 | N/A |
| 12/31/2022 | 21 | 27 | 11 | 11 | N/A |
| 9/30/2022 | 22 | 10 | 15 | 15 | N/A |
| 6/30/2022 | 21 | 8 | 11 | 11 | N/A |
| 3/31/2022 | 22 | 9 | 11 | 11 | N/A |
| 12/31/2021 | 22 | 8 | 14 | 14 | N/A |
| 9/30/2021 | 22 | 5 | 14 | 14 | N/A |
| 6/30/2021 | 23 | 6 | 12 | 12 | N/A |
| 3/31/2021 | 21 | 3 | 11 | 11 | N/A |
| 12/31/2020 | 22 | 4 | 11 | 12 | N/A |
| 9/30/2020 | 21 | 7 | 7 | 7 | N/A |
| 6/30/2020 | 22 | 3 | 10 | 11 | N/A |
| 3/31/2020 | 23 | 4 | 11 | 12 | N/A |
| 12/31/2019 | 22 | 3 | N/A | 8 | N/A |
| 9/30/2019 | 23 | -1 | N/A | 8 | N/A |
| 6/30/2019 | 22 | 2 | N/A | 6 | N/A |
| 3/31/2019 | 23 | 3 | N/A | 2 | N/A |
| 12/31/2018 | 23 | 1 | N/A | 8 | N/A |
| 9/30/2018 | 28 | 6 | N/A | 13 | N/A |
| 6/30/2018 | 34 | 9 | N/A | 18 | N/A |
| 3/31/2018 | 37 | 11 | N/A | 19 | N/A |
| 12/31/2017 | 40 | 11 | N/A | 13 | N/A |
| 9/30/2017 | 34 | 7 | N/A | 11 | N/A |
| 6/30/2017 | 32 | 5 | N/A | 9 | N/A |
| 3/31/2017 | 31 | 1 | N/A | 10 | N/A |
| 12/31/2016 | 30 | 4 | N/A | 11 | N/A |
| 9/30/2016 | 33 | 6 | N/A | 8 | N/A |
| 6/30/2016 | 34 | 2 | N/A | 7 | N/A |
| 3/31/2016 | 34 | 1 | N/A | 7 | N/A |
| 12/31/2015 | 34 | 2 | N/A | 8 | N/A |
| 9/30/2015 | 32 | 3 | N/A | 12 | N/A |
| 6/30/2015 | 30 | 13 | N/A | 16 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: CPH 의 연간 예상 수익 증가율(2.1%)이 saving rate(3%) 미만입니다.
수익 vs 시장: CPH 의 연간 수익(2.1%)이 Canadian 시장(10.8%)보다 느리게 성장할 것으로 예상됩니다.
고성장 수익: CPH 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.
수익 대 시장: CPH 의 수익(연간 8.2%)이 Canadian 시장(연간 4.6%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: CPH 의 수익(연간 8.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: CPH의 자본 수익률은 3년 후 14%로 낮을 것으로 예상됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/20 02:30 |
| 종가 | 2026/05/20 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Cipher Pharmaceuticals Inc.는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Novak | ATB Cormark Historical (Cormark Securities) |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Prakash Gowd | CIBC Capital Markets |